Sector News

India’s Cipla gets U.S. beachhead with $550M deal for 2 generics operations

September 7, 2015
Life sciences

India’s Cipla made its name in the west as a leader in challenging Big Pharma patents on expensive drugs in an effort to cut their prices in a country with a large need and little money. But it has lagged behind its compatriots in challenging U.S. drugmakers on their own turf, currently getting less than 10% of its revenues from the lucrative U.S. market. The company is making moves to change that equation, announcing a small deal on Friday to buy two U.S. focused generics companies.

Cipla said it will pay $550 million for InvaGen Pharmaceuticals, a Hauppauge, NY-based generics maker with 32 products in the market and 30 in the pipeline, as well as Exelan Pharmaceuticals, a Lawrenceville, GA, operation that markets and sells InvaGen’s products into the government and institutional markets. It said with InvaGen, it also gets a 350,000-square-foot manufacturing plant–its first production facility in the U.S.–an R&D operation and 500 employees.

Global CEO Subhanu Saxena in a statement called the buy a good fit for his company that is “in line with its strategy to grow Cipla’s share in the U.S. pharmaceutical market.” InvaGen CEO Sudhakar Vidiyala said the deal allows his company to tap global markets.

Other Indian drugmakers have grown into sizable operations by feeding the demand from the U.S. for cheap generics. Sun Pharmaceutical’s $4 billion buyout this year of troubled Ranbaxy Laboratories was in large part an effort to quickly build U.S. market share. Before regulator problems undermined its efforts, Ranbaxy had won many first-to-file generics approvals for blockbuster drugs like for Pfizer’s Lipitor and Novartis’ blockbuster Diovan and AstraZeneca’s Nexium. The melded operations of the two are expected to generate $2.3 billion in U.S. sales for Sun, half of total revenues.

Other Indian drugmakers also are following that same playbook, buying U.S. operations to get more financial heft in the States as well as executives that know the ropes in the country. Lupin in July snapped up GAVIS Pharmaceutical, a New Jersey company founded by Veerappan Subramanian, paying $880 million to nail down its first U.S. manufacturing site and a portfolio of products.

Cipla has obviously been in the hunt for a U.S. deal and was mentioned along with Lupin as a potential bidder for UCB’s U.S.-based generics business. That instead went this week in a $1.23 billion deal to Lannett ($LCI), a rapidly growing U.S. generics maker. And Cipla has been forging deals with partners in other parts of the world. In April it said it had paid $418 million to buy a Brazilian drug distributor and earlier did deals in Morocco, Iran and Yemen, countries where western drugmakers are still uncertain about making moves.

Even with the InvaGen deal, Cipla’s sales in the U.S. will be relatively small. Surajit Pal, an analyst at Prabhudas Lilladher Pvt. in Mumbai said that “With their own growth and these acquisitions, their sales in the U.S. may reach $450 million to $500 million.” But Pal said the deal allows Cipla to “fill a gap,” in its business.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend